IMVT
Live chart
What they do
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
For information only · Important disclosures
Grades vs sector
No sector grades for IMVT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.61 | -0.68 | -10.5% |
| 2026-05-20 | -0.63 | -0.67 | -7.5% |
| 2026-02-06 | -0.69 | -0.54 | +22.4% |
| 2025-11-10 | -0.73 | -0.65 | +10.6% |
| 2025-08-11 | -0.67 | -0.71 | -5.4% |
| 2025-05-29 | -0.72 | -0.64 | +10.7% |
| 2025-02-06 | -0.75 | -0.76 | -1.0% |
| 2024-11-07 | -0.59 | -0.74 | -24.5% |
Insider trades
$71.8K
$42.5K
$51.2K
$70.9K
$119.6K
$103.5K
$64.9K
$135.0K
$59.7K
$110.5K
$263.0K
Stats refreshed 2026-10-21 18:06:02 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026